Spegra Tablet is a combination antiretroviral medication used for the treatment of HIV (Human Immunodeficiency Virus) infection. Dolutegravir, Emtricitabine, and Tenofovir Alafenamide are its three active ingredients; they all perform together to inhibit viral replication and boost immunity.

Brand Name: Spegra

Composition: Dolutegravir, Emtricitabine, and Tenofovir Alafenamide

Mechanism of Action:

Dolutegravir: Prevents the integration of viral DNA into the host genome, which is essential for the virus's replication, by inhibiting the integrase enzyme.
Emtricitabine: Prevents viral RNA from being converted to DNA by inhibiting the reverse transcriptase enzyme. Like emtricitabine, tenofovir alafenamide works against HIV by blocking the virus's ability to replicate by inhibiting reverse transcriptase.

Uses:

HIV Infection

Dosage and Administration:

One tablet taken once a day, with or without food, is the usual dosage.

Side Effects:

• Fatigue
• Headache
• Nausea
• Vomiting
• Fever
• Cough
• Insomnia
• Liver Function Abnormalities
• Allergic Reactions

Safety Advise:

Kidney  

Monitor kidney function regularly, as spegra can cause nephrotoxicity. Kindly speak with your healthcare provider.

Liver  

Monitor liver function regularly, as spegra can cause liver impairement. Kindly speak with your healthcare provider.

Pregnancy  

Spegra should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using spegra while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Alcohol  

Spegra should not be taken with alcohol. Kindly speak with your healthcare provider.

Storage:

Store Spegra Tablet at a temperature between 15°C and 30°C (59°F to 86°F). Keep the tablets in the original packaging to protect them from light and moisture. Keep out of reach of children.

References:

1.    Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. 2017 Nov 4;390(10107):2073-82.

2.   Venter WD, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV. 2020 Oct 1;7(10):e666-76.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Emcure Pharmaceuticals Ltd

Address: 255/2, Hinjawadi, Pune - 411057, India

Country of origin: India